[Federal Register Volume 85, Number 168 (Friday, August 28, 2020)]
[Notices]
[Pages 53390-53391]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-18988]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive Patent License: Anti-CD56 as an 
Antibody-Drug Conjugate (``ADC'') or Non-ADC To Target Glioblastoma 
Either Alone or in Combination With Other Potential Immuno-Oncology 
Drugs.

AGENCY: National Institutes of Health, Health and Human Services. 
(HHS).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Cancer Institute, an institute of the National 
Institutes of Health, Department of Health and Human Services, is 
contemplating the grant of an Exclusive Patent License to practice the 
inventions embodied in the Patents and Patent Applications listed in 
the Supplementary Information section of this notice to Connectyx 
Technologies Holdings Group (``Connectyx'') located in Boca Raton, FL.

DATES: Only written comments and/or applications for a license which 
are received by the National Cancer Institute's Technology Transfer 
Center on or before September 14, 2020 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
and comments relating to the contemplated an Exclusive Patent License 
should be directed to: Jasmine Yang, Ph.D., Senior Licensing and 
Patenting Manager at Telephone: (240)-276-5530 or at Email: 
[email protected].

SUPPLEMENTARY INFORMATION:

Intellectual Property

(1) U.S. Provisional Patent Application No. 62/119,707 filed July 31, 
2015. HHS Ref No. E-221-2015-0-US-01
(2) PCT Application No. PCT/US2016/044777 filed 07/29/2016. HHS Ref. 
No. E-221-2015-0-PCT-02
(3) U.S. Patent No. 10,548,987 issued February 02, 2020 (Patent 
Application No. 15/747,620 filed January 25, 2018). HHS Ref. No. E-221-
2015-0-US-03.

    The patent rights in these inventions have been assigned and/or 
exclusively licensed to the government of the United States of America.
    The prospective exclusive license territory may be worldwide and 
the field of use may be limited to the use of Licensed Patent Rights 
for the following: Anti-CD56 as an antibody-drug conjugate (``ADC'') to 
target and treat glioblastoma either alone or in

[[Page 53391]]

combination with other potential immuno-oncology drugs.
    This technology discloses the composition of an ADC comprising a 
drug conjugated to CD56-specific monoclonal antibodies, m900 and m906, 
or an antigen-binding fragment, wherein the drug comprises a cytotoxic 
agent, including but not limited to PBD, and to methods of using the 
ADCs for treating neuroblastoma, small-cell lung cancer, multiple 
myeloma, acute myeloid leukemia, NK-T lymphoma, and neuroendocrine 
cancer. This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and the prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published notice, the National 
Cancer Institute receives written evidence and argument that 
establishes that the grant of the license would not be consistent with 
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
    In response to this Notice, the public may file comments or 
objections. Comments and objections, other than those in the form of a 
license application, will not be treated confidentially, and may be 
made publicly available.
    License applications submitted in response to this Notice will be 
presumed to contain business confidential information and any release 
of information in these license applications will be made only as 
required and upon a request under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: August 20, 2020.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2020-18988 Filed 8-27-20; 8:45 am]
BILLING CODE 4140-01-P